Skip to content

Study · Animal study (in vivo) · rat · 1989

12 results

MIF-1 attenuates apomorphine stereotypies in adult rats after neonatal 6-hydroxydopamine.

Kostrzewa RM, White TG, Zadina JE, Kastin AJ

European journal of pharmacology1 Apr 1989Cited by 10 (Europe PMC)

PMID2568266 (opens in a new tab)DOI10.1016/0014-2999(89)90392-0 (opens in a new tab)PepBankPUB-02568266
Publisher pagePubMedAsk about this study
Jump to 12 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study12

10 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In rats exposed to neonatal 6-OHDA, MIF‑1 attenuated the increased distance traveled after low-dose apomorphine.

    In plain wordsIn rats exposed to neonatal 6-OHDA, MIF‑1 reduced increased travel distance compared with the group without MIF‑1.

    Peptide
    MIF-1 (Pro-Leu-Gly-NH2)
    Outcome
    DecreaseDistance traveled after low-dose apomorphine
    Study

    ratn: not reported in source

    neonatal 6-hydroxydopamine exposure
    Comparator
    6-OHDA group without MIF-1
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    2.0 mg/kg per day · subcutaneous · 7 or 8 daysAs given in this study (rat).

    Source sentences

    Summary
    MIF-1 (x 7 or 8 days) showed a tendency to attenuate the increased number of movements and significantly (P less than 0.05) reduced all of the other effects of neonatal 6-OHDA.
    2 context sentences
    Summary · context
    At 5 weeks, a low dose (0.1 mg/kg s.c.) of apomorphine increased the distance traveled, time in ambulation, number of stereotypic movements, and number of movements per time in stereotypy, but decreased the time in stereotypy in the 6-OHDA group.
    Summary · context
    Rats received 6-OHDA (100 micrograms i.c.v.) or diluent at 3 days after birth and either MIF-1 (2.0 mg/kg per day s.c. x 10 days) or diluent beginning at 28 or 29 days after birth.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In rats exposed to neonatal 6-OHDA, MIF‑1 attenuated the increased ambulation time after low-dose apomorphine.

    In plain wordsIn rats exposed to neonatal 6-OHDA, MIF‑1 reduced increased walking time compared with the group without MIF‑1.

    Peptide
    MIF-1 (Pro-Leu-Gly-NH2)
    Outcome
    DecreaseTime in ambulation after low-dose apomorphine
    Study

    ratn: not reported in source

    neonatal 6-hydroxydopamine exposure
    Comparator
    6-OHDA group without MIF-1
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    2.0 mg/kg per day · subcutaneous · 7 or 8 daysAs given in this study (rat).

    Source sentences

    Summary
    MIF-1 (x 7 or 8 days) showed a tendency to attenuate the increased number of movements and significantly (P less than 0.05) reduced all of the other effects of neonatal 6-OHDA.
    2 context sentences
    Summary · context
    At 5 weeks, a low dose (0.1 mg/kg s.c.) of apomorphine increased the distance traveled, time in ambulation, number of stereotypic movements, and number of movements per time in stereotypy, but decreased the time in stereotypy in the 6-OHDA group.
    Summary · context
    Rats received 6-OHDA (100 micrograms i.c.v.) or diluent at 3 days after birth and either MIF-1 (2.0 mg/kg per day s.c. x 10 days) or diluent beginning at 28 or 29 days after birth.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In rats exposed to neonatal 6-OHDA, MIF‑1 tended to attenuate the increased number of movements after low-dose apomorphine.

    In plain wordsIn rats exposed to neonatal 6-OHDA, MIF‑1 tended to reduce increased movements compared with the group without MIF‑1.

    Peptide
    MIF-1 (Pro-Leu-Gly-NH2)
    Outcome
    DecreaseNumber of stereotypic movements
    Study

    ratn: not reported in source

    neonatal 6-hydroxydopamine exposure
    Comparator
    6-OHDA group without MIF-1
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    2.0 mg/kg per day · subcutaneous · 7 or 8 daysAs given in this study (rat).

    Source sentences

    Summary
    MIF-1 (x 7 or 8 days) showed a tendency to attenuate the increased number of movements and significantly (P less than 0.05) reduced all of the other effects of neonatal 6-OHDA.
    2 context sentences
    Summary · context
    At 5 weeks, a low dose (0.1 mg/kg s.c.) of apomorphine increased the distance traveled, time in ambulation, number of stereotypic movements, and number of movements per time in stereotypy, but decreased the time in stereotypy in the 6-OHDA group.
    Summary · context
    Rats received 6-OHDA (100 micrograms i.c.v.) or diluent at 3 days after birth and either MIF-1 (2.0 mg/kg per day s.c. x 10 days) or diluent beginning at 28 or 29 days after birth.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In rats exposed to neonatal 6-OHDA, MIF‑1 attenuated the increased movements per time in stereotypy after low-dose apomorphine.

    In plain wordsIn rats exposed to neonatal 6-OHDA, MIF‑1 reduced increased repetitive movement frequency compared with the group without MIF‑1.

    Peptide
    MIF-1 (Pro-Leu-Gly-NH2)
    Outcome
    DecreaseMovements per time in stereotypy
    Study

    ratn: not reported in source

    neonatal 6-hydroxydopamine exposure
    Comparator
    6-OHDA group without MIF-1
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    2.0 mg/kg per day · subcutaneous · 7 or 8 daysAs given in this study (rat).

    Source sentences

    Summary
    MIF-1 (x 7 or 8 days) showed a tendency to attenuate the increased number of movements and significantly (P less than 0.05) reduced all of the other effects of neonatal 6-OHDA.
    2 context sentences
    Summary · context
    At 5 weeks, a low dose (0.1 mg/kg s.c.) of apomorphine increased the distance traveled, time in ambulation, number of stereotypic movements, and number of movements per time in stereotypy, but decreased the time in stereotypy in the 6-OHDA group.
    Summary · context
    Rats received 6-OHDA (100 micrograms i.c.v.) or diluent at 3 days after birth and either MIF-1 (2.0 mg/kg per day s.c. x 10 days) or diluent beginning at 28 or 29 days after birth.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In rats exposed to neonatal 6-OHDA, MIF‑1 attenuated the decreased time in stereotypy after low-dose apomorphine.

    In plain wordsIn rats exposed to neonatal 6-OHDA, MIF‑1 reduced the loss of repetitive behavior time compared with the group without MIF‑1.

    Peptide
    MIF-1 (Pro-Leu-Gly-NH2)
    Outcome
    IncreaseTime in stereotypy
    Study

    ratn: not reported in source

    neonatal 6-hydroxydopamine exposure
    Comparator
    6-OHDA group without MIF-1
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    2.0 mg/kg per day · subcutaneous · 7 or 8 daysAs given in this study (rat).

    Source sentences

    Summary
    MIF-1 (x 7 or 8 days) showed a tendency to attenuate the increased number of movements and significantly (P less than 0.05) reduced all of the other effects of neonatal 6-OHDA.
    2 context sentences
    Summary · context
    At 5 weeks, a low dose (0.1 mg/kg s.c.) of apomorphine increased the distance traveled, time in ambulation, number of stereotypic movements, and number of movements per time in stereotypy, but decreased the time in stereotypy in the 6-OHDA group.
    Summary · context
    Rats received 6-OHDA (100 micrograms i.c.v.) or diluent at 3 days after birth and either MIF-1 (2.0 mg/kg per day s.c. x 10 days) or diluent beginning at 28 or 29 days after birth.
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    In rats exposed to neonatal 6-OHDA, MIF‑1 did not attenuate reduced licking after higher-dose apomorphine.

    In plain wordsIn rats exposed to neonatal 6-OHDA, MIF‑1 did not reverse reduced licking compared with the group without MIF‑1.

    Peptide
    MIF-1 (Pro-Leu-Gly-NH2)
    Outcome
    No significant changeLicking after higher-dose apomorphine
    Study

    ratn: not reported in source

    neonatal 6-hydroxydopamine exposure
    Comparator
    6-OHDA group without MIF-1
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    2.0 mg/kg per day · subcutaneous · 10 daysAs given in this study (rat).

    Source sentences

    Summary
    Behavior induced by higher doses of apomorphine in the 6-OHDA group (reduced licking and head nodding; increased paw treading, taffy pulling and self-biting) were not attenuated by MIF-1.
    1 context sentence
    Summary · context
    Rats received 6-OHDA (100 micrograms i.c.v.) or diluent at 3 days after birth and either MIF-1 (2.0 mg/kg per day s.c. x 10 days) or diluent beginning at 28 or 29 days after birth.
  7. 07AnimalAnimal study (in vivo)Efficacy outcome

    In rats exposed to neonatal 6-OHDA, MIF‑1 did not attenuate reduced head nodding after higher-dose apomorphine.

    In plain wordsIn rats exposed to neonatal 6-OHDA, MIF‑1 did not reverse reduced head nodding compared with the group without MIF‑1.

    Peptide
    MIF-1 (Pro-Leu-Gly-NH2)
    Outcome
    No significant changeHead nodding after higher-dose apomorphine
    Study

    ratn: not reported in source

    neonatal 6-hydroxydopamine exposure
    Comparator
    6-OHDA group without MIF-1
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    2.0 mg/kg per day · subcutaneous · 10 daysAs given in this study (rat).

    Source sentences

    Summary
    Behavior induced by higher doses of apomorphine in the 6-OHDA group (reduced licking and head nodding; increased paw treading, taffy pulling and self-biting) were not attenuated by MIF-1.
    1 context sentence
    Summary · context
    Rats received 6-OHDA (100 micrograms i.c.v.) or diluent at 3 days after birth and either MIF-1 (2.0 mg/kg per day s.c. x 10 days) or diluent beginning at 28 or 29 days after birth.
  8. 08AnimalAnimal study (in vivo)Efficacy outcome

    In rats exposed to neonatal 6-OHDA, MIF‑1 did not attenuate increased paw treading after higher-dose apomorphine.

    In plain wordsIn rats exposed to neonatal 6-OHDA, MIF‑1 did not reverse increased paw treading compared with the group without MIF‑1.

    Peptide
    MIF-1 (Pro-Leu-Gly-NH2)
    Outcome
    No significant changePaw treading after higher-dose apomorphine
    Study

    ratn: not reported in source

    neonatal 6-hydroxydopamine exposure
    Comparator
    6-OHDA group without MIF-1
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    2.0 mg/kg per day · subcutaneous · 10 daysAs given in this study (rat).

    Source sentences

    Summary
    Behavior induced by higher doses of apomorphine in the 6-OHDA group (reduced licking and head nodding; increased paw treading, taffy pulling and self-biting) were not attenuated by MIF-1.
    1 context sentence
    Summary · context
    Rats received 6-OHDA (100 micrograms i.c.v.) or diluent at 3 days after birth and either MIF-1 (2.0 mg/kg per day s.c. x 10 days) or diluent beginning at 28 or 29 days after birth.
  9. 09AnimalAnimal study (in vivo)Efficacy outcome

    In rats exposed to neonatal 6-OHDA, MIF‑1 did not attenuate increased taffy pulling after higher-dose apomorphine.

    In plain wordsIn rats exposed to neonatal 6-OHDA, MIF‑1 did not reverse increased taffy pulling compared with the group without MIF‑1.

    Peptide
    MIF-1 (Pro-Leu-Gly-NH2)
    Outcome
    No significant changeTaffy pulling after higher-dose apomorphine
    Study

    ratn: not reported in source

    neonatal 6-hydroxydopamine exposure
    Comparator
    6-OHDA group without MIF-1
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    2.0 mg/kg per day · subcutaneous · 10 daysAs given in this study (rat).

    Source sentences

    Summary
    Behavior induced by higher doses of apomorphine in the 6-OHDA group (reduced licking and head nodding; increased paw treading, taffy pulling and self-biting) were not attenuated by MIF-1.
    1 context sentence
    Summary · context
    Rats received 6-OHDA (100 micrograms i.c.v.) or diluent at 3 days after birth and either MIF-1 (2.0 mg/kg per day s.c. x 10 days) or diluent beginning at 28 or 29 days after birth.
  10. 10AnimalAnimal study (in vivo)Efficacy outcome

    In rats exposed to neonatal 6-OHDA, MIF‑1 did not attenuate increased self-biting after higher-dose apomorphine.

    In plain wordsIn rats exposed to neonatal 6-OHDA, MIF‑1 did not reverse increased self-biting compared with the group without MIF‑1.

    Peptide
    MIF-1 (Pro-Leu-Gly-NH2)
    Outcome
    No significant changeSelf-biting after higher-dose apomorphine
    Study

    ratn: not reported in source

    neonatal 6-hydroxydopamine exposure
    Comparator
    6-OHDA group without MIF-1
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    2.0 mg/kg per day · subcutaneous · 10 daysAs given in this study (rat).

    Source sentences

    Summary
    Behavior induced by higher doses of apomorphine in the 6-OHDA group (reduced licking and head nodding; increased paw treading, taffy pulling and self-biting) were not attenuated by MIF-1.
    1 context sentence
    Summary · context
    Rats received 6-OHDA (100 micrograms i.c.v.) or diluent at 3 days after birth and either MIF-1 (2.0 mg/kg per day s.c. x 10 days) or diluent beginning at 28 or 29 days after birth.

Studies that did not test the peptide alone2

In this study, MIF-1 (Pro-Leu-Gly-NH2) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking MIF-1 (Pro-Leu-Gly-NH2).

  1. 11AnimalNot a test of MIF-1 (Pro-Leu-Gly-NH2) aloneAnimal study (in vivo)Efficacy outcome

    In rats, striatal SCH-23390 binding was unaltered in all groups, including groups treated with MIF‑1.

    In plain wordsIn rats, striatal SCH-23390 binding did not change in any group, including groups treated with MIF‑1.

    Peptide
    MIF-1 (Pro-Leu-Gly-NH2)
    Outcome
    No significant changeStriatal SCH-23390 binding
    Study

    ratn: not reported in source

    neonatal 6-hydroxydopamine exposure
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition

    Source sentences

    Summary
    At 38 or 39 days, total in vitro binding of [3H]SCH-23390 and [3H]spiroperidol to striatal homogenates was not altered in any of the groups.
    1 context sentence
    Summary · context
    Rats received 6-OHDA (100 micrograms i.c.v.) or diluent at 3 days after birth and either MIF-1 (2.0 mg/kg per day s.c. x 10 days) or diluent beginning at 28 or 29 days after birth.

    In this study, MIF-1 (Pro-Leu-Gly-NH2) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking MIF-1 (Pro-Leu-Gly-NH2).

  2. 12AnimalNot a test of MIF-1 (Pro-Leu-Gly-NH2) aloneAnimal study (in vivo)Efficacy outcome

    In rats, striatal spiroperidol binding was unaltered in all groups, including groups treated with MIF‑1.

    In plain wordsIn rats, striatal spiroperidol binding did not change in any group, including groups treated with MIF‑1.

    Peptide
    MIF-1 (Pro-Leu-Gly-NH2)
    Outcome
    No significant changeStriatal spiroperidol binding
    Study

    ratn: not reported in source

    neonatal 6-hydroxydopamine exposure
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition

    Source sentences

    Summary
    At 38 or 39 days, total in vitro binding of [3H]SCH-23390 and [3H]spiroperidol to striatal homogenates was not altered in any of the groups.
    1 context sentence
    Summary · context
    Rats received 6-OHDA (100 micrograms i.c.v.) or diluent at 3 days after birth and either MIF-1 (2.0 mg/kg per day s.c. x 10 days) or diluent beginning at 28 or 29 days after birth.

    In this study, MIF-1 (Pro-Leu-Gly-NH2) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking MIF-1 (Pro-Leu-Gly-NH2).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.